RESEARCH ARTICLE

Effects of TNF Secreting HEK Cells on B Lymphocytes’ Apoptosis in Human Chronic Lymphocytic Leukemias

Armita Valizadeh\(^1,2\), Ahmad Ahmadzadeh\(^3\), Ali Teimoori\(^4\), Ali Khodadadi\(^5\), Ghasem Saki\(^1,2*\)

Abstract

**Background:** Tumor necrosis factor (TNF) related apoptosis-inducing ligand (TRAIL) is an antitumor candidate in cancer therapy. This study focused on effects of TRAIL, as a proapoptotic ligand that causes apoptosis, in B-CELL chronic lymphocytic leukemia cells (B-CLL).

**Materials and Methods:** A population of HEK 293 cells was transducted by lentivirus that these achieved ability for producing the TRAIL protein and then HEK 293 cells transducted were placed in the vicinity of CLL cells. After 24 hours of co-culture, apoptosis of CLL cells was assessed by annexin V staining.

**Results:** The amount of Apoptosis was examined separately in four groups: 293 HEK TRAIL (16.17±1.04%); 293 HEK GFP (2.7±0.57%); WT 293 HEK (2±2.6%); and CLL cells (0.01±0.01%). Among the groups studied, the maximum amount of apoptosis was in the group that the vector encoding TRAIL was transducted. In this group, the mean level of soluble TRAIL in the culture medium was 253pg/ml; also flow cytometry analyzes showed that proapotosis in this group was 32.8±1.6%, which was higher than the other groups.

**Conclusions:** In this study, we have demonstrated that TNF secreted from HEK 293 cells are effective in death of CLL cells.

Keywords: B-CELL chronic lymphocytic leukemia - tumor necrosis factor-related apoptosis-inducing ligand

Asian Pac J Cancer Prev, 15 (22), 9885-9889

Introduction

B-CELL chronic lymphocytic leukemia (B-CLL) is one of the common leukemia in the western countries that men are more affected with (Weirnik et al., 1991). In this type of leukemia, apoptosis of cells become deficient and long life; and the proliferation rate of 0.1% to greater than 1% per day. In final, some colonies of B-cells are formed in peripheral blood and lymphoid organs and bone marrow (Lagneaux et al., 1998; Kay et al., 2007).

Today, Leukemias are treated with surgery, chemotherapy and radiotherapy but response to these treatments is very weak and metastatic cancers remain in the body; so, looking out the new treatments are necessary (Loebinger et al., 2009).

Nowadays, Tumor necrosis factor (TNF) -related apoptosis-inducing ligand (TRAIL) is a candidate for cancer therapy (Ashkenazi et al., 1999) that as a death ligand, without affecting the normal cells, may cause apoptosis in a variety of human tumors; in fact, this ligand is a part of the immune system that helps prevent the formation and spread of tumors (Wiley et al., 1995; Mahalingam et al., 2009). By binding to the death receptors (DR) particularly on TRAIL-R1/DR4 and TRAIL-R2/DR5 this ligand causes to form the death complex, and ultimately apoptosis (Sprick et al., 2000).

In this study, The HEK 293 cells were transducted with a vector that encodes the human TRAIL gene and the green fluorescent protein (MIGR1-TRAIL-GFP). The studies suggest that the modification of HEK 293 cells with a vector that encodes TRAIL gene, express a protein that is released naturally as a soluble ligand into the environment (Wiley et al., 1995) and environmental factors in the adjacent of CLL cells affect the survival of them (Panayiotidis et al., 1996; Lagneaux, et al., 1998).

In this study, the effect of Hek cells new

Materials and Methods

To produce viral particles, 24 hours before transfection, HEK 293 cells were cultured in a 10 cm plate 2.5 × 10\(^6\), when confluency of cells reached approximately 60-70% lentiviral plasmids containing transgene of the full-length human TRAIL with fluorescent proteins (MIGR1-TRAIL-GFP) were transducted with a rate of 10µg along with packaging plasmid psPAX2 and envelope plasmid pMD2 each were mixed with Lipofectamine with quantities of 5µg and according to the protocol of lipofectamin 2000

\(^1\)Department of Anatomy, \(^2\)Physiology Research Center, School of Medicine, \(^3\)Thalassemia and Hemoglobinopathies Research Center, Shafa Hospital, \(^4\)Virology Department, \(^5\)Cancer, Petroleum and Environmental Pollutants Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran *For correspondence: ghasemsaki@yahoo.com
Co-culture of CLL cells with HEK 293

The next day (day two) the HEK 293 cells transduced by confluent monolayer were observed by fluorescent inverted microscope (Olympus IX 71) and after confirmation of GFP expression, these cells were co-cultured with B-CLL cells. Before co-culture, the live CLL cells that were isolated the same time (by a method described above) were detected using Trypan blue dye and counted by hemocytometer and in the second day were added to the studied groups in a certain proportion (with three repeats per each group).

The ratio of HEK cells to the cancer cells was approximately 1 to 5, which ability of HEK cell transducted for the death of CLL cell was examined during 24 hours of co-culture. The amount of the TRAIL molecule in the form of solution ligand in the culture medium was assessed in the days of two and three. In the third day the CLL cells floating in the medium were collected but the most of the CLL cells adhered strictly to the cells on the floor of the plate (HEK cells). The CLL cells were isolated with pipetting genetly and exactly by ice-cold phosphate-buffered saline (NwaboKamdje et al., 2012).

ELISA.

An amount (with an amount of 100µl) of supernatant of the cell culture was removed in the second and third days and amount of the solution TRAIL in the culture medium was examined.

Samples were performed with human quantikine enzyme-linked immune sorbent assay (ELISA) kit as described by the manufacturer. Briefly, the ELISA plates were incubated with samples for one hour at 37°C, washed with wash buffer, and subsequently they were incubated with Detector antibody for one hour washed in the wash buffer. After addition of Streptavidin- HRP conjugate for 30 min, washed with wash buffer, dispense substrate and incubate in the dark for 30 minutes and colorimetric changes were measured at 450nm/630nm.

Apoptotic assay

Therefore, briefly HEK 293 cells were cultured in the 24-home plate (the day of zero). It is necessary to mention that in the fourth group only medium was added and then in the upcoming 24 hours (the first day) HEK 293 cells were transducted. On the second day after isolating the cancer cells, the co-culture with HEK 293 cells transducted and untransducted with the same ratio that was mentioned, was conducted. In the fourth group also CLL cells were cultured alone. After 24 hours of the co-culture, by collecting the cancer cells in the third day, apoptosis rate was assessed by annexin V (eBioscience) staining by fluorescence-activated cell sorting (FACS).

Statistical analysis

Data were tested using the Kruskal-Wallis and one-way analysis of variance test and Post Hoc Tukey test to compare multiple groups as well as internal comparison between multiple groups; in addition, data were analyzed using the EXELL 2010 and SPSS 19 and P value with ≤0.05 was considered statistically significant.

Results

The HEK cells were transducted by lentiviruses (as described above), and these cells are capable for expressing the human TRAIL (MIGR1-TRAIL-GFP) after 24 hours. The HEK cells, which their genes were modified by TRAIL-encoding vector, are able to produce the related protein in the form of the solution ligand in the culture medium. The amount of the solution TRAIL in the culture medium in the second day in all groups, whether in a group or not transducted (WT HEK, CLL), is extremely low (12.3±0.5pg/ml); however, on day 3 in the HEK TRAIL group (253±25.1pg/ml) significantly increased but the rest of the group had no significant change on day 3 (Figure 1).
When observing the HEK cells by florescent inverted microscope in the groups one and two, which were transducted by vector encoding the TRAILGFP gene, due to the GFP expression the green points were seen in these two groups that these points were in more and more specific rates (Figure 2). On the third day after collecting cancer cells the annexin V staining was used for examining the apoptosis rate in these cells. After analyzing the flow cytometry data the rate of apoptosis and proapoptosis in these groups was determined (Figure 3). PI-positive staining cells in co-culture are necrosis, cells that were positive by annexin V, were affected by proapoptosis and cancer cells that were positive by annexin V and PI, were apoptosis.

Table 1 shows the mean proapoptosis and necrosis apoptosis rate in each four groups separately. As it can be seen, a considerable difference exists between the HEKTRAIL group with other groups in proapoptosis and apoptosis rate. A significant difference exists in cancer cells (p<0.05) between the HEKTRAIL group with other groups (Table 2). The results show that no significant difference exists between three groups that have not modified by TRAIL gene (Table 3).

### Discussion

Cancer is the main cause of death throughout the world so that during 2010 in USA 25% of the deaths in all ages is related to the cancer (1).

So, the cancer necessitates new treatments. Today lentiviruses vectors, which are prepared by an immune deficient virus, are used for gene therapy. This virus is a strong tool for providing gene to the different cells. Nowadays lentiviruses vectors are used for providing gene in the laboratory environment and in the human body. The 293THEK cells are able to produce lentiviruses vectors; in
this study these cells have been used. By gene modification of these cells the TRAIL is made and released in a soluble form. Today, Adipose-derived mesenchymal stem cells (AD-MSD) are transduced by lentiviruses and used as a constant source for producing the soluble TRAIL. The TRAIL has this feature that can be used as an antitumor factor on the tumor cells and their metastases (Loebinger et al., 2009), oral cancer (Chen et al., 2013), glioma (Kim et al., 2009), cervical carcinoma (Grisendi et al., 2010). Because it causes the death selectively only in the tumor cells not in the normal cells (Walczak et al., 1999; and Duiker et al., 2006). Recently this antitumor ligand has been used in the studies that results of all these studies show an antitumor effect of the TRAIL: oral cancer (Chen et al., 2013), glioma (Kim et al., 2009), cervical carcinoma (Grisendi et al., 2010).

Since no certain treatment exists yet for CLL disease, in this study we used TRAIL, for apoptosis of CLL cells. This molecule in the form of the solution releases into the environment. On the third day, really 48 hours after transduction, the amount of this ligand in the culture medium has had a considerable increase. The past studies have reported that the secretion of TRAIL begins six hours after the transduction and its rate of the release in 12, 24 and 48 hours after the transduction is constant that it is more than 366.4 pg/ml (Grisendi et al., 2010). Compared with the results of other studies, the amount of soluble TRAIL in our study is lower, which can be due to lack of virus titration; in addition, titration and the concentration of the virus by doing transduction the performance increases and more cells would be enforced to release TRAIL. In GFP Vector and other groups at all times the amount of soluble TRAIL has been the non-measurable (Grisendi G et al., 2010) but our data on average (12.3±0.5 pg/ml) has shown perhaps all the cells release a very slight amount of the TRAIL.

In this study, the data suggest that CLL cells are sensitive to TRAIL so that even with the optical microscope it can be observed that with the passage of time more dead cells will be more evident in the environment so that the flow cytometry analysis also have confirmed apoptosis of CLL cells. In this study, the cancer cells have been only 24 hours in the vicinity of the TRAIL, and among the groups, the HEK TRAIL group has had a higher proapoptosis and apoptosis. Of course, this difference can be justified due to the higher concentration of the TRAIL in the cell culture environment.

On the other hand, compared to study conducted by Cho SA et al., 2011, the low level of TRAIL effect in CLL cells against brain stem Glioma can be due to the low concentration of the TRAIL in the cell culture medium that is not enough to stimulate the cancer cell death Or it can be due to the slight time of adjacency of the cancer cells to TRAIL or a change in the ratio of the HEK cells to the cancer cells, meaning that perhaps the number of HEK cells is not enough to feed the tumor. With the increase in HEK cells compared to cancer cells cancer cells may be placed in the vicinity of more TRAIL. As can be observed in table 1, in the HEK TRAIL group the percentage of cells that are in proapoptotic phase 32.8% is higher apoptosis 16.6%. More time may be needed until the cells have ample opportunity to enter into a phase of apoptosis.

The TRAIL can be used also in combination with effective factors in inducing the apoptosis in the treatments; thus the efficiency of TRAIL can be increased (Zhao B et al., 2011 Jiang et al., 2013; HengXu et al., 2014).

In this study, not only as an anti-proliferative effect or even as a powerful inhibitory the TRAIL ligand is able to affect on CLL cells. With consideration of the impact of TRAIL on CLL cells and due to lower durability HEK cell, in future Adipose-derived mesenchymal stem cells (AD-MSD) will be used for delivering TRAIL.

Acknowledgements

We thank Razavi MH, Poorbigravanvand SH, for technical assistance; Mohammadi for help with flow cytometry analysis, as well as thank Ahvaz Jundishapur University of Medical Sciences (AJUMS) to financial support.

References

Ashkenazi A, Pai RC, Fong S, et al (1999). Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest, 104, 155-62.

Chen FC, Zhang F, Zhang ZJ, et al (2013). Tumor necrosis factor-α gene polymorphisms and risk of oral cancer: evidence from a meta-analysis. Asian Pac J Cancer Prev, 14, 7243-9.

Choi SA, Hwang SK, Wang KC, et al (2011). Therapeutic efficacy and safety of TRAIL: producing human adipose tissue - derived mesenchymal stem cells against experimental brainstem glioma. Neuro Oncol, 13, 61-9.

Duiker EW, Mom CH, de Jong S, et al (2006). The clinical trial of TRAIL. Eur J Cancer, 42, 2233-40.

Grisendi G, Bussolari R, Cafarelli L, et al (2010). Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res, 70, 3718-29.

HengXu, Yan-Na Tian, Bo-Ying Dun, et al (2014). A Novel Monoclonal Antibody Induces Cancer Cell Apoptosis and Enhances the Activity of Chemotherapeutic Drugs. Asian Pac J Cancer Prev, 15, 4423-8.

Jiang L, Hao JL, Jin ML et al (2013). Effect of embelin on TRAIL receptor 2 mAb-induced apoptosis of TRAIL-resistant A549 non-small cell lung cancer cells. Asian Pac J Cancer Prev, 14, 6115-20.

Kay NE, Shanafelt TD, Strege AK, et al (2007). Bone biopsy derived marrow stromalelements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced celldeath and facilitates an "angiogeneic switch". Leuk Res, 31, 899-906.

Kim SM, Lim JY, Park SI, et al (2008). Gene therapy using TRAIL-secreting human umbilical cord blood derived mesenchymal stem cells against intracranial glioma. Cancer Res, 68, 9614-23.

Lagneaux L, Delforge A, Bron D, et al (1998). Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood, 91, 2387-96.

Loebinger MR, Eddaoudi A, Davies D, et al (2009). Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res, 69, 4134-42.

Mahalingam D, Szegedi E, Keane M, et al (2009). TRAIL receptor signalling and modulation: Are we on the right
TRAIL? Cancer Treat Rev., 35, 280-8.
Messmer BT, Messmer D, Allen SL, et al (2005). In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest, 115, 755-64.
Montserrat E (2002). Current and developing chemotherapy for CLL. Med Oncol. 19, 11-19.
Nwabo Kamdje AH, Bassi G, Pacelli L, et al (2012). Role of stromal cell-mediated Notch signaling in CLL resistance to chemotherapy. Blood Cancer Journal, 2, 73
Panayiotidis P, Jones D, Ganeshaguru K, et al (1996). Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol, 92, 97-103.
Seiffert M, Schulz A, Ohl S, et al (2010). Soluble CD14 is a novel monocyte-derived survival factor for chronic lymphocytic leukemia cells, which is induced by CLL cells in vitro and present at abnormally high levels in vivo. Blood, 116, 4223-30.
Sprick MR, Weigand MA, Rieser E, et al (2000). FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity, 12, 599-609.
Walczak H, Miller RE, Ariail K, et al (1999). Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand In vivo. Nat Med, 5, 157-63.
Wiley SR, Schooley K, Smolak PJ, et al (1995). Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 3, 673-82.
Zhao B, Li L, Cui K, et al (2011). Mechanisms of TRAIL and gemcitabine induction of pancreatic cancer cell apoptosis. Asian Pac J Cancer Prev, 12, 2675-8.